Propanc Biopharma, Inc. PPCB
1.78 USD +0.05 (+3.19%)
Regular-session close
1.73 -0.05 -2.81%
After hours · Nov 20, 4:00 PM ET
1.77 Day range 2.00
1.64 52-week range 235.63
- YTD
- -98.67%
- 1 year
- -99.14%
5D -0.12 (-6.27%)
- Market cap
- 1.87M
- EPS (ttm)
- -95.92
- YTD return
- -98.67%
- 1-year return
- -99.14%
- Volume
- 27.87K
- Avg volume
- 188.26K
- Open
- 1.79
- Previous close
- 1.73
- Day's range
- 1.77 – 2.00
- 52-week range
- 1.64 – 235.63
Fundamental scorecard
4 of 25 checks passed on PPCB’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
PPCB Revenue — quarterly 0
PPCB Net income — quarterly -8.59M
PPCB EPS — quarterly -12.22
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | 0.00 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.01 | — | — |
| Feb 20, 2024 | Dec 1, 2023 | 0.00 | -0.03 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -0.04 | — | — |
| Sep 27, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | 0.00 | 0.00 | — | — |
News
Propanc Biopharma Continues Clinical Development Program For Propanc Proenzyme; Targets February 2027 For Its First Clinical Site Initiation
Propanc Biopharma Announces New Preclinical Data Supporting Potential Of PRP To Treat Chemotherapy Resistance In Pancreatic Cancer; PRP Monotherapy Reduced Cancer Cell Proliferation By ~50–54% And Suppressed Long-term Clonogenic Survival By Up To 59%
Propanc Biopharma Announces 1-For-10 Reverse Stock Split, Effective Oct. 26
Your note
Sign in to keep a note on PPCB — it syncs with the Stock Master app.
